Premium
P4‐660: TRIPLE THERAPY WITH MASUPIRDINE (SUVN‐502), A 5‐HT 6 ANTAGONIST, DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER'S DISEASE: BASELINE PATIENT CHARACTERISTICS IN A PHASE‐2A STUDY
Author(s) -
Nirogi Ramakrishna,
Ravulu Jyothsna,
Jetta Satish,
Goyal Vinod Kumar,
Pandey Santosh Kumar,
Mudigonda Koteshwara,
Jasti Venkat
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.09.026
Subject(s) - donepezil , memantine , placebo , dementia , medicine , clinical endpoint , population , clinical dementia rating , mini–mental state examination , clinical trial , psychology , disease , alternative medicine , environmental health , pathology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom